Skip to content

Acute Responses to Manipulating Dietary Carbohydrate Content on Free-living Physical Activity Energy Expenditure

Acute Responses to Manipulating Dietary Carbohydrate Content on Free-living Physical Activity Energy Expenditure

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03917810
Enrollment
25
Registered
2019-04-17
Start date
2018-01-01
Completion date
2021-09-01
Last updated
2022-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physical Activity

Keywords

Nutrition, Carbohydrates, Ketogenic, Metabolism

Brief summary

Dietary sugar and carbohydrate intakes will be manipulated for 3 days in a randomised crossover design. All food will be provided. Free-living physical activity energy expenditure will be measured using combined heart rate and accelerometry. Metabolic and appetite/mood responses to 3 days on each diet will be measured. Each participant will undergo 3 days of each diet: 1. Moderate sugar - reflecting the composition of a typical European diet 2. Low sugar - similar macronutrient composition of a typical European diet but with \<5% energy intake from free sugars (as per government guidelines) 3. Low carbohydrate - low carbohydrate diet with \<5% energy intake from sugar and \<8% energy intake from carbohydrate, replacing carbohydrate energy with fat

Detailed description

Guidelines calling for dietary free sugars to be reduced have been formulated from evidence that diets high in sugar are associated with high energy intake. In theory, by reducing the intake of sugars, calorie surplus will be reduced and energy balance will be maintained. However, when referring to interventions/behaviours that influence energy balance, both sides of the energy balance equation need to be considered. Alterations in nutrients may influence aspects of energy expenditure, not solely energy intake, and this may have implications for the efficacy of guidelines seeking to influence energy intake. It is important to consider energy expenditure in the context of health. The most variable component of energy expenditure between individuals is physical activity energy expenditure (PAEE), which varies from \ 600-2100 kcal per day in men of a similar demographic. Current guidelines do not regard the effect that changing dietary sugar might have on PAEE and therefore total energy expenditure. Furthermore, there is increasing interest in restricting overall carbohydrate intake to treat metabolic disease or achieve ketogenesis. Very little is known about nutrition-physical activity interactions with this type of intervention. This study will prescribe 3 diets to healthy males for 3 days in a randomised crossover design, where each participant will consume each of the diets. All food will be prepared and provided by the study team. The diets are as follows: 1. Moderate sugar - reflecting the composition of a typical European diet 2. Low sugar - similar macronutrient composition of a typical European diet but with \<5% energy intake from free sugars (as per government guidelines) 3. Low carbohydrate - low carbohydrate diet with \<5% energy intake from sugar and \<8% energy intake from carbohydrate, replacing carbohydrate energy with fat

Interventions

OTHERDiet

Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated

Sponsors

University of Bath
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Randomised crossover design

Eligibility

Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index 18.5-29.9 kg∙m-2 * Age 18-65 years * Male * Able and willing to provide informed consent and safely comply with study procedures * No anticipated changes in physical activity during the study (e.g. holidays)

Exclusion criteria

* Any reported condition or behaviour deemed either to pose undue personal risk to the participant or introduce bias * Any diagnosed metabolic disease (e.g. type 1 or type 2 diabetes)•Any reported use of substances which may pose undue personal risk to the participants or introduce bias into the experiment * Lifestyle not conforming to standard sleep-wake cycle (e.g. shift worker) * Any reported recent (\<6 months) change in body mass (±3%)

Design outcomes

Primary

MeasureTime frameDescription
Physical activity energy expenditure (kj/day or kcal/day)3 daysPhysical activity energy expenditure measured using individually-calibrated combined heart rate and accelerometry (kj/day or kcal/day)

Secondary

MeasureTime frameDescription
Energy expended in different physical activity intensities (MET categories) (kJ/day or kcal/day)3 daysEnergy expended in different physical activity intensities (MET categories) (kJ/day or kcal/day) using individually-calibrated combined heart rate and accelerometry
Energy expended in the postprandial period (kJ or kcal)3 daysEnergy expended in the postprandial period (kJ or kcal) measured using individually-calibrated combined heart rate and accelerometry
Fasting blood glucose concentrations3 daysMeasures of blood glucose concentrations pre- and post-intervention.
Fasting blood insulin concentrations3 daysMeasures of blood insulin concentrations pre- and post-intervention.
Fasting blood triglyceride concentrations3 daysMeasures of blood triglyceride concentrations pre- and post-intervention.
Fasting blood non-esterified fatty acid concentrations3 daysMeasures of blood non-esterified fatty acid concentrations pre- and post-intervention.
Fasting blood lactate concentrations3 daysMeasures of blood lactate concentrations pre- and post-intervention.
Fasting blood beta-hydroxybutyrate concentrations3 daysMeasures of blood beta-hydroxybutyrate concentrations pre- and post-intervention.
Time spent in different physical activity intensities (MET categories) (minutes)3 daysTime spent in different physical activity intensities (MET categories) (minutes) using individually-calibrated combined heart rate and accelerometry
Fasting blood fibroblast growth factor-21 concentrations3 daysMeasures of blood fibroblast growth factor-21 concentrations pre- and post-intervention.
Fasting blood total cholesterol concentrations3 daysMeasures of blood total cholesterol concentrations pre- and post-intervention.
Fasting blood high density lipoprotein concentrations3 daysMeasures of blood high density lipoprotein concentrations pre- and post-intervention.
Fasting blood low density lipoprotein concentrations3 daysMeasures of blood low density lipoprotein concentrations pre- and post-intervention.
Food preference ratings3 daysFood preference ratings determined by computer task measured pre- and post-intervention
Subjective appetite and mood ratings3 daysMeasured by 0-100 mm visual analogue scales measured pre- and post-intervention
Blood pressure3 daysBlood pressure using an automated sphygmomanometer pre- and post-intervention
Fasting blood leptin concentrations3 daysMeasures of blood leptin concentrations pre- and post-intervention.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026